Most Shorted Stocks
DYN is part of our most shorted stocks screen list, indicating it has a high short interest.
DYNE THERAPEUTICS INC (DYN) Stock Price & Overview
NASDAQ:DYN • US26818M1080
Current stock price
17.39 USD
-0.16 (-0.91%)
At close:
17.39 USD
0 (0%)
After Hours:
The current stock price of DYN is 17.39 USD. Today DYN is down by -0.91%. In the past month the price decreased by -7.7%. In the past year, price increased by 46.63%.
DYN Key Statistics
52-Week Range8.06 - 25
Current DYN stock price positioned within its 52-week range.
1-Month Range17.21 - 21.43
Current DYN stock price positioned within its 1-month range.
- Market Cap
- 2.87B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.54
- Dividend Yield
- N/A
DYN Stock Performance
Today
-0.91%
1 Week
-4.76%
1 Month
-7.70%
3 Months
-2.79%
Longer-term
6 Months -22.98%
1 Year +46.63%
2 Years -45.45%
3 Years +33.46%
5 Years -9.00%
10 Years N/A
DYN Stock Chart
DYN Stock Screens
DYN currently appears in the following ChartMill screener lists.
DYN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to DYN. When comparing the yearly performance of all stocks, DYN is one of the better performing stocks in the market, outperforming 78.07% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
DYN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DYN. While DYN seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DYN Earnings
Next Earnings DateJul 27, 2026
Last Earnings DateApr 30, 2026
PeriodQ4 / 2025
EPS Reported-$0.76
Revenue Reported
EPS Surprise 2.28%
Revenue Surprise %
DYN Forecast & Estimates
20 analysts have analysed DYN and the average price target is 40.73 USD. This implies a price increase of 134.23% is expected in the next year compared to the current price of 17.39.
Analysts
Analysts84
Price Target40.73 (134.22%)
EPS Next Y15.57%
Revenue Next YearN/A
DYN Index Membership
DYN is currently included in the following stock indexes tracked on ChartMill.
DYN Financial Highlights
Over the last trailing twelve months DYN reported a non-GAAP Earnings per Share(EPS) of -3.54. The EPS decreased by -5.67% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-446.21M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.59% | ||
| ROE | -45.9% | ||
| Debt/Equity | 0.15 |
Chartmill High Growth Momentum
EPS Q2Q%13.64%
Sales Q2Q%N/A
EPS 1Y (TTM)-5.67%
Revenue 1Y (TTM)N/A
DYN Ownership
Ownership
Inst Owners109.68%
Shares165.03M
Float154.96M
Ins Owners0.45%
Short Float %14.01%
Short Ratio9.92
DYN Industry Overview
DYN operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
DYN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DYN
Company Profile
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 258 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Company Info
IPO: 2020-09-17
DYNE THERAPEUTICS INC
1560 Trapelo Road
Waltham MASSACHUSETTS 02451 US
CEO: Joshua Brumm
Employees: 258
Phone: 18009279800
DYNE THERAPEUTICS INC / DYN FAQ
Can you describe the business of DYNE THERAPEUTICS INC?
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 258 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Can you provide the latest stock price for DYNE THERAPEUTICS INC?
The current stock price of DYN is 17.39 USD. The price decreased by -0.91% in the last trading session.
Does DYNE THERAPEUTICS INC pay dividends?
DYN does not pay a dividend.
What is the ChartMill rating of DYNE THERAPEUTICS INC stock?
DYN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is DYNE THERAPEUTICS INC (DYN) stock traded?
DYN stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for DYNE THERAPEUTICS INC?
DYNE THERAPEUTICS INC (DYN) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of DYN stock?
DYNE THERAPEUTICS INC (DYN) has a market capitalization of 2.87B USD. This makes DYN a Mid Cap stock.